Description: Essay stating Americans need to invent, implement, and evaluate sustainable health care policies, divert cash-flow streams away from projects which feed the beast and focus on projects and policies which enhance value. It will require a combination of thoughtful, coordinated policies and a change in our cultural expectations of infinite resources and unlimited choice.

Description: This article explores what American medicine might look like in the year 2000. The author asserts this will depend on the tradeoffs made between quality and availability on the one hand, and cost on the other hand.

Description: Recap of Q&A sessions held to discuss the findings and methodology of a SOA study on the cost of the newly insured under the ACA.

Description: An essay discussing universal access to high quality, low cost health care.

Description: This session is about rationing health care. From Record of Society of Actuaries Vol. 18, No. 4A.

Description: Brief discussion of future anticipated health reform and information on papers discussing these reforms. Topics include Medicare, individual insurnace, tax credits & subsidies, pre-Medicare retirees and Medicaid

Description: Two nonactuarial experts representing opposing health care reform solutions present their alternative views. From Record of Society of Actuaries Vol. 20, No. 3A.

Description: The author provides an overview of the Chinese health care system from its beginnings in in 1949 to the present day launching of the most comprehensive reform ever.

Description: Panel discussion of prospects for cost containment of, and alternatives to, fee-for-service health care, and management of health care under national health insurance. Discussion points include cost containment devices, HMOs, economic impact, cost escalation, self-insurance, stop-loss, claims administration, loss of state premium taxes, and Phase 3 tax problems under NH1.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.